Curanex Pharmaceuticals Inc Common Stock (CURX)

About CURX

Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma Inc. and changed its…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Website

www.curanexpharma.com

Fundamentals

1-day range

$0.2162$0.23

Market cap

$5.53M

P/E (trailing)

—

P/E (forward)

—

EPS (trailing)

$-0.02

Dividend yield

—

Beta

—

Avg. volume

88.8K

Curanex Pharmaceuticals Inc Common Stock Competitors

Chosen by industry and closest market cap.

• CURX

  Curanex Pharmaceuticals Inc Common Stock

  $4.56

  ▼ 2.56%
  Market cap $5.53MP/E —
  $0.179$9.18
• NCNA

  NuCana plc American Depositary Share

  $1.79

  ▲ 21.43%
  Market cap $5.66MP/E 0.01
  $1.21$7.22
• BGMS

  Bio Green Med Solution Inc. Common Stock

  $0.86

  ▼ 3.37%
  Market cap $5.35MP/E 0.18
  $0.5664$8.82
• GOVX

  GeoVax Labs Inc. Common Stock

  $0.7195

  ▲ 0.35%
  Market cap $5.31MP/E —
  $0.59$19.2
• LABT

  Lakewood-Amedex Biotherapeutics Inc. Common Stock

  $2.3

  ▼ 4.56%
  Market cap $5.28MP/E —
  $0.366$9.82
• ERNA

  Ernexa Therapeutics Inc. Common Stock

  $4.57

  ▼ 4.99%
  Market cap $5.09MP/E —
  $3.18$71.5
• PULM

  Pulmatrix Inc. Common Stock

  $1.51

  ▼ 0.66%
  Market cap $6.06MP/E —
  $1.16$5.5

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
  Benzinga · 8/5/2026

Institutional Ownership

March 31, 2026

Total shares held

327.8K

Total value held

$167.6K

Institutional holders

8